Parkinson Disease: A Review of Treatment Guidelines, Healthcare Utilization Data, and Emerging Therapies

Parkinson Disease: A Review of Treatment Guidelines, Healthcare Utilization Data, and Emerging Therapies

Faculty Presenter

Winston Wong, PharmD
President
W-Squared Group
Longboat Key, Florida
 
Program Description
Approximately 60,000 Americans are diagnosed with Parkinson disease (PD) each year, with an economic burden of at least $14 billion that is expected to double by 2040. Several key challenges and unmet medical needs exist in the PD treatment landscape. Guidelines addressing treatment of PD with and without motor symptom involvement were last published in 2006 and 2010 by the American Academy of Neurology and have since been retired. As no disease-modifying therapies yet exist to address the underlying pathology of PD, decisions about when to initiate treatment are often debated and represent a major limitation for pharmacists and managed care professionals. Current treatment options are also associated with frequent adverse effects that may be dose-limiting for patients, further impairing tolerability and diminishing patient quality of life. Polypharmacy with adjunctive medications is often required and compounds direct medical costs. Managed care professionals and pharmacists should keep abreast of the status of ongoing research for therapeutic agents for PD with the potential to prevent complications that contribute to increased healthcare resource utilization and poor clinical outcomes. This activity will provide a review of the current treatment landscape of PD and an in-depth overview of emerging disease-modifying therapies under development.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: November 18, 2020
Expiration date: November 18, 2021
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Examine the rising prevalence of Parkinson disease including the clinical and economic burden
• Identify the current standard of care for Parkinson disease including clinical trial data for new and emerging treatments
• Explore the place in therapy and potential impact of new and emerging treatments for Parkinson disease

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-371-H01-P. The activity is available for CE credit through November 18, 2021.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Winston Wong, PharmD, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms